Armata Pharmaceuticals ARMP 深 沪
等待开盘 11-12 09:30:00 美东时间
3.89
+0.140
+3.73%
华盛通- 最 高3.89
- 今 开3.73
- 成交量 5.05万股
- 最 低 3.57
- 昨 收 3.75
- 总市值 1.45亿
- 52周最高 14.98
- 市盈率 静 --
- 换手率 0.14%
- 52周最低 2.745
- 委 比 20.63%
- 总股本 3718.20万
- 历史最高 16.34
- 量 比 0.73
- 振 幅 8.53%
- 历史最低 0.8311
- 每 手 1
- 风险率 2.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
09-24 16:10
Armata secures new U.S. funding for AP-SA02 Phase 3
Armata Pharmaceuticals ( ($ARMP) ) has shared an announcement. On September 23,...
09-23 19:28
Armata Pharmaceuticals Receives Additional $3.7M In Non-dilutive Funds From US Department Of War For Phase 3 Development Program For AP-SA02
Importantly, the $3.7 million represents the first funding received specifically for Phase 3 execution pursuant to a previously announced DoW award, received through the Medical Technology Enterprise Consortium ("MTEC") and managed by the Naval Medical Research Command ("NMRC") – Naval Advanced Medi...
09-23 19:09
Armata Pharmaceuticals Receives FDA Breakthrough Therapy Designation For Its Intravenously Administered Staphylococcus Aureus Multi-Phage Product Candidate AP-SA02
Designation for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus ("MSSA") or methicillin-resistant S. aureus ("MRSA"). Breakthrough Therapy designation is intended to expedite the review of medicines that treat a serious or life-threatening condition and have sho...
09-14 19:07
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over available thera...
09-14 19:00
Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.45) by 38.64 percent. This is a 40 percent increase over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $2.510 milli...
08-13 04:29
Why Is Armata Pharma Stock Gaining Monday?
Armata Pharmaceuticals Inc. (NYSE:ARMP) stock is trading higher on Monday after the company announced significant clinical, regulatory, manufacturing, and operational progress supporting the advancement of its lead therapeutic candidate, AP-SA02. The late clinical-stage biotechnology business is mov...
07-21 00:45
Armata股价因超级细菌疗法晚期试验进展而飙升
Armata Pharmaceuticals股价周一上涨，此前该公司表示其实验性超级细菌疗法AP-SA02向启动晚期试验迈出了重要一步。 早盘交易中，...
07-20 23:48
Armata Pharmaceuticals shares are trading higher after the company reported clinical, regulatory, manufacturing, and operational progress advancing AP‑SA02 toward a planned Phase 3 study in complicated Staphylococcus aureus bacteremia.
Armata Pharmaceuticals shares are trading higher after the company reported clinical, regulatory, manufacturing, and operational progress advancing AP‑SA02 toward a planned Phase 3 study in complicated Staphylococcus aureus bacteremia.
07-20 22:35
Armata推进AP-SA02临床与生产进程 计划启动Ⅲ期试验
生物制药公司Armata Pharmaceuticals周一宣布，其在研噬菌体疗法AP-SA02在临床、监管和生产方面均取得关键进展，为计划中的Ⅲ期临床试验...
07-20 22:32
